Amgen (AMGN): Good AMG334 Migraine Results, But Not Differentiated - Leerink
- Top 10 News for 9/19 - 9/23: Twitter on the Auction Block; Allergan Bolsters NASH Effort; Microsoft Returns Value
- Wall Street falls as energy lags; shares post gains on week
- Rumored Forever, Twitter (TWTR) May Have Finally Put the 'For Sale' Sign Up
- Facebook (FB) Shares Under Pressure on Reports Video Ad Metrics Were Artificially Inflated
- Brookfield Infrastructure (BIP)-Led Consortium to Take Controlling Stake in Petrobras' (PBR) NTS for $5.2B
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Leerink Partners, Geoffrey Porges, reiterated his Market Perform rating on shares of Amgen (NASDAQ: AMGN) after Amgen revealed the secondary endpoints of its phase 2 chronic migraine trial for erenumab this week at the European Headache and Migraine Trust International Congress in Glasgow.
The study met its key secondary endpoint, the proportion of patients experiencing at least a 50% reduction in migraine days, with both dose cohorts (70mg and 140mg monthly SC) achieving statistical significance vs. placebo (40% and 41%, respectively, vs. 24%). These values, however, failed to differentiate erenumab from competing programs from Alder (NASDAQ: ALDR) and Teva (NYSE: TEVA) – although the results continue to validate the class of CGRP targets for the treatment of migraines.
Shares of Amgen closed at $172.64 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Approves Amgen's (AMGN) Biosimilar to AbbVie's (ABBV) Humira
- Jefferies Increases Estimates on A.O. Smith (AOS) - PT to $111
- Roth Capital Keeps BioLineRx (BLRX) at 'Buy' Amid New in-Licensing Agreement
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!